胰激肽原酶与依那普利治疗糖尿病肾病的对照研究  

Comparative study on effect of kallidinogenase and enalapril in treating diabetic nephropathy

作　　者：赵伟河[1] 田永红[1] 王守林[1] 宋士军[1] 

机构地区：[1]河南第一荣康医院内分泌科,新乡453003

出　　处：《中国医师进修杂志》2006年第6期9-11,共3页Chinese Journal of Postgraduates of Medicine

摘　　要：目的探讨治疗糖尿病肾病(DN)的有效方法。方法将72例糖尿病肾病患者分为三组,分别为胰激肽原酶组、依那普利组和对照组,治疗前后观察血糖、血压、尿白蛋白排出率(UAER)、血尿素氮(BUN)、血肌酐(Cr)的变化情况,并进行统计学分析。结果治疗后胰激肽原酶组和依那普利组患者UAER均较对照组明显降低,差异有统计学意义(P<0.01);胰激肽原酶组患者治疗后Cr水平较依那普利组和对照组均明显降低,差异有统计学意义(P均<0.05);依那普利组患者治疗后收缩压(SBP)和舒张压(DBP)较治疗前差异有统计学意义(P<0.05),较对照组治疗后差异有统计学意义(P<0.05);胰激肽原酶组SBP较治疗前差异有统计学意义(P<0.05)。结论胰激肽原酶和依那普利均有较好治疗糖尿病肾病的效果,胰激肽原酶还可以改善患者的肾功能。Objective To investigate the effective treatment on diabetic nephropathy. Methods Seventy - two patients with diabetic nephropathy were divided into three groups： kallidinogenase group, enalapril group, and the control group. They were treated by kaUidinogenase, enalapfil or as a control. Prior and post treatment, determine the levels of glocose, blood pressure, urinary albumin excretion rate, blood urea nitrogen,and serum creatinine. Results Post treatment,both kallidinogenase and enalapfil group , urinary albumin excretion rate were obviously decreased than control group, P 〈 0.01. The levels of blood pressure were significantly lower than before, P 〈 0.05. The serum creatinine level of kallidinogenase group was decreased than enalapril group and control group, P 〈 0.05. Conclusions Kallidinogenase and enalapril are effect on treating diabetic nephropathy, and the former can improve renal function.

关 键 词：胰激肽原酶 依那普利 糖尿病肾病 

分 类 号：R587.2[医药卫生—内分泌]